BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, October 18, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Guangzhou Vinnocent Pharmaceutical presents new inhibitors of CYP11B1 and CYP11B2
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Endocrine/Metabolic
Guangzhou Vinnocent Pharmaceutical presents new inhibitors of CYP11B1 and CYP11B2
April 16, 2024
No Comments
Guangzhou Vinnocent Pharmaceutical Ltd. has divulged cytochrome P450 11B1, mitochondrial (CYP11B1; steroid 11-β-monooxygenase) and cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of anxiety disorders, Cushing syndrome, cancer, diabetic nephropathy, fibromyalgia, heart failure, nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis [MASH]) and obesity, among others.
BioWorld Science
Endocrine/metabolic
Patents